Literature DB >> 25478293

High altitude illnesses in Hawai'i.

Terry Shin1.   

Abstract

High Altitude Headache (HAH), Acute Mountain Sickness (AMS), and High Altitude Cerebral Edema (HACE) are all high altitude related illnesses in order of severity from the mildly symptomatic to the potentially life-threatening. High altitude illnesses occur when travelers ascend to high altitudes too rapidly, which does not allow enough time for the body to adjust. Slow graded ascent to the desired altitude and termination of ascent if AMS symptoms present are keys to illness prevention. Early recognition and rapid intervention of AMS can halt progression to HACE. Pharmacologic prophylaxis with acetazolamide is a proven method of prevention and treatment of high altitude illness. If prevention fails then treatment modalities include supplemental oxygen, supportive therapy, hyperbaric treatment, and dexamethasone. Given the multitude of visitors to the mountains of Hawai'i, high altitude illness will continue to persist as a prevalent local condition. This paper will emphasize the prevention and early diagnosis of AMS so that the illness does not progress to HACE.

Entities:  

Mesh:

Year:  2014        PMID: 25478293      PMCID: PMC4244895     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  10 in total

Review 1.  High-altitude illness.

Authors:  P H Hackett; R C Roach
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

Review 2.  High-altitude illness.

Authors:  Scott A Gallagher; Peter H Hackett
Journal:  Emerg Med Clin North Am       Date:  2004-05       Impact factor: 2.264

Review 3.  The physiologic basis of high-altitude diseases.

Authors:  John B West
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

4.  Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.

Authors:  Andrew M Luks; Scott E McIntosh; Colin K Grissom; Paul S Auerbach; George W Rodway; Robert B Schoene; Ken Zafren; Peter H Hackett
Journal:  Wilderness Environ Med       Date:  2010-03-10       Impact factor: 1.518

Review 5.  High altitude ataxia--its assessment and relevance.

Authors:  Brynn A Bird; Alexander David Wright; Mark H Wilson; Brian G Johnson; Chris H Imray
Journal:  Wilderness Environ Med       Date:  2011-06       Impact factor: 1.518

6.  Acute mountain sickness.

Authors:  J S Milledge
Journal:  Thorax       Date:  1983-09       Impact factor: 9.139

7.  Survey of acute mountain sickness on Mauna Kea.

Authors:  Janet Onopa; Amanda Haley; Mei Ean Yeow
Journal:  High Alt Med Biol       Date:  2007       Impact factor: 1.981

8.  Treatment of acute mountain sickness: hyperbaric versus oxygen therapy.

Authors:  J F Kasic; M Yaron; R A Nicholas; J A Lickteig; R Roach
Journal:  Ann Emerg Med       Date:  1991-10       Impact factor: 5.721

Review 9.  The cerebral effects of ascent to high altitudes.

Authors:  Mark H Wilson; Stanton Newman; Chris H Imray
Journal:  Lancet Neurol       Date:  2009-02       Impact factor: 44.182

Review 10.  Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis.

Authors:  Emma V Low; Anthony J Avery; Vaibhav Gupta; Angela Schedlbauer; Michael P W Grocott
Journal:  BMJ       Date:  2012-10-18
  10 in total
  2 in total

1.  High altitude increases the expression of hypoxia-inducible factor 1α and inducible nitric oxide synthase with intest-inal mucosal barrier failure in rats.

Authors:  Fangxin Zhang; Wenming Wu; Zhiyun Deng; Xiaofeng Zheng; Jiucong Zhang; Shangxin Deng; Jiayu Chen; Qiang Ma; Yong Wang; Xiaohui Yu; Shengchao Kang; Xiufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Thickened Retinal Nerve Fiber Layers Associated With High-Altitude Headache.

Authors:  Xianhong Yin; Yi Li; Yanyun Ma; Yuan Xie; Kun Wang; Dayan Sun; Xiaoyu Liu; Meng Hao; Meng Liang; Shixuan Zhang; Yuan Guo; Li Jin; Ningli Wang; Jiucun Wang
Journal:  Front Physiol       Date:  2022-05-04       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.